Differential Prognostic Value of Revascularization for Coronary Stenosis With Intermediate FFR by Coronary Flow Reserve.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
23 05 2022
Historique:
received: 13 12 2021
revised: 21 01 2022
accepted: 25 01 2022
pubmed: 1 5 2022
medline: 24 5 2022
entrez: 30 4 2022
Statut: ppublish

Résumé

The authors sought to evaluate comparative prognosis between deferred versus performed percutaneous coronary intervention (PCI) according to coronary flow reserve (CFR) values of patients with intermediate fractional flow reserve (FFR). For coronary stenosis with intermediate FFR, the prognostic value of PCI remains controversial. The prognostic impact of PCI may be different according to CFR in patients with intermediate FFR. From the ILIAS Registry (Inclusive Invasive Physiological Assessment in Angina Syndromes Registry, N = 2,322), 400 patients (412 vessels) with intermediate FFR (0.75-0.80) were selected. Patients were stratified into preserved CFR (>2.0, n = 253) and depressed CFR (≤2.0, n = 147) cohorts. Per-vessel clinical outcomes during 5 years of follow-up were compared between deferred versus performed PCI groups in both cohorts. The primary outcome was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization. Among the study population, PCI was deferred for 210 patients (219 vessels, 53.2%) (deferred group) and performed for 190 patients (193 vessels, 46.8%) (performed group). The risk of TVF was comparable between the deferred and performed groups (12.8% vs 14.2%; adjusted HR: 1.403; 95% CI: 0.584-3.369; P = 0.448). When stratified by CFR, PCI was performed in 39.1% (100/261 vessels) of the preserved CFR cohort and 61.9% (93/151 vessels) of the depressed CFR cohort. Within the preserved CFR cohort, the risk of TVF did not differ significantly between the deferred and performed groups (11.0% vs 13.9%; adjusted HR: 0.770; 95% CI: 0.262-2.266; P = 0.635). However, in the depressed CFR cohort, the deferred group had a significantly higher risk of TVF than the performed group (17.2% vs 14.2%; adjusted HR: 4.932; 95% CI: 1.312-18.53; P = 0.018). A significant interaction was observed between CFR and the treatment decision (interaction P = 0.049). Results were consistent after inverse probability weighting adjustment. In patients with intermediate FFR of 0.75 to 0.80, the prognostic value of PCI differed according to CFR, with a significant interaction. PCI was associated with a lower risk of TVF compared with the deferral strategy when CFR was depressed (≤2.0), but there was no difference when CFR was preserved (>2.0). CFR could be used as an additional risk stratification tool to determine treatment strategies in patients with intermediate FFR. (Inclusive Invasive Physiological Assessment in Angina Syndromes Registry [ILIAS Registry]; NCT04485234).

Sections du résumé

OBJECTIVES
The authors sought to evaluate comparative prognosis between deferred versus performed percutaneous coronary intervention (PCI) according to coronary flow reserve (CFR) values of patients with intermediate fractional flow reserve (FFR).
BACKGROUND
For coronary stenosis with intermediate FFR, the prognostic value of PCI remains controversial. The prognostic impact of PCI may be different according to CFR in patients with intermediate FFR.
METHODS
From the ILIAS Registry (Inclusive Invasive Physiological Assessment in Angina Syndromes Registry, N = 2,322), 400 patients (412 vessels) with intermediate FFR (0.75-0.80) were selected. Patients were stratified into preserved CFR (>2.0, n = 253) and depressed CFR (≤2.0, n = 147) cohorts. Per-vessel clinical outcomes during 5 years of follow-up were compared between deferred versus performed PCI groups in both cohorts. The primary outcome was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization.
RESULTS
Among the study population, PCI was deferred for 210 patients (219 vessels, 53.2%) (deferred group) and performed for 190 patients (193 vessels, 46.8%) (performed group). The risk of TVF was comparable between the deferred and performed groups (12.8% vs 14.2%; adjusted HR: 1.403; 95% CI: 0.584-3.369; P = 0.448). When stratified by CFR, PCI was performed in 39.1% (100/261 vessels) of the preserved CFR cohort and 61.9% (93/151 vessels) of the depressed CFR cohort. Within the preserved CFR cohort, the risk of TVF did not differ significantly between the deferred and performed groups (11.0% vs 13.9%; adjusted HR: 0.770; 95% CI: 0.262-2.266; P = 0.635). However, in the depressed CFR cohort, the deferred group had a significantly higher risk of TVF than the performed group (17.2% vs 14.2%; adjusted HR: 4.932; 95% CI: 1.312-18.53; P = 0.018). A significant interaction was observed between CFR and the treatment decision (interaction P = 0.049). Results were consistent after inverse probability weighting adjustment.
CONCLUSIONS
In patients with intermediate FFR of 0.75 to 0.80, the prognostic value of PCI differed according to CFR, with a significant interaction. PCI was associated with a lower risk of TVF compared with the deferral strategy when CFR was depressed (≤2.0), but there was no difference when CFR was preserved (>2.0). CFR could be used as an additional risk stratification tool to determine treatment strategies in patients with intermediate FFR. (Inclusive Invasive Physiological Assessment in Angina Syndromes Registry [ILIAS Registry]; NCT04485234).

Identifiants

pubmed: 35490124
pii: S1936-8798(22)00419-8
doi: 10.1016/j.jcin.2022.01.297
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04485234']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1033-1043

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Joo Myung Lee has received research grants from Abbott and Philips. Dr Mejia-Renteria has received speaker fees from Philips, Abbott, and Medis. Dr Echavarria-Pinto has received speaker fees from Abbott and Philips. Dr van de Hoef has received speaker fees and institutional research grants from Abbott and Philips. Dr van Royen has received speaker fees and institutional research grants from Abbott and Philips. Dr Koo has received institutional research grants from Abbott Vascular and Philips Volcano. Dr Piek has received support as a consultant for Philips/Volcano; and has received institutional research grants from Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Juwon Kim (J)

Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Doosup Shin (D)

Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.

Joo Myung Lee (JM)

Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: drone80@hanmail.net.

Seung Hun Lee (SH)

Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.

David Hong (D)

Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Ki Hong Choi (KH)

Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Doyeon Hwang (D)

Seoul National University Hospital, Department of Internal Medicine, Cardiovascular Center, Seoul, Korea.

Coen K M Boerhout (CKM)

Department of Cardiology, Amsterdam University Medical Center, Academic Medical Center, Amsterdam, the Netherlands.

Guus A de Waard (GA)

Department of Cardiology, Amsterdam University Medical Center, VU University Medical Center, Amsterdam, the Netherlands.

Ji-Hyun Jung (JH)

Sejong General Hospital, Sejong Heart Institute, Bucheon, Korea.

Hernan Mejia-Renteria (H)

Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.

Masahiro Hoshino (M)

Department of Cardiology, Tsuchiura Kyodo General Hospital, Tsuchiura City, Japan.

Mauro Echavarria-Pinto (M)

Hospital General Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estad Querétaro, Facultad de Medicina, Universidad Autónoma de Querétaro, Querétaro, Mexico.

Martijn Meuwissen (M)

Department of Cardiology, Amphia Hospital, Breda, the Netherlands.

Hitoshi Matsuo (H)

Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.

Maribel Madera-Cambero (M)

Department of Cardiology, Tergooi Hospital, Blaricum, the Netherlands.

Ashkan Eftekhari (A)

Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Mohamed A Effat (MA)

Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, Ohio, USA.

Tadashi Murai (T)

Department of Cardiology, Tsuchiura Kyodo General Hospital, Tsuchiura City, Japan.

Koen Marques (K)

Department of Cardiology, Amsterdam University Medical Center, VU University Medical Center, Amsterdam, the Netherlands.

Joon-Hyung Doh (JH)

Department of Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.

Evald H Christiansen (EH)

Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Rupak Banerjee (R)

Department of Mechanical and Materials Engineering, University of Cincinnati, Veterans Affairs Medical Center, Cincinnati, Ohio, USA.

Hyun Kuk Kim (HK)

Department of Internal Medicine and Cardiovascular Center, Chosun University Hospital, University of Chosun College of Medicine, Gwangju, Korea.

Chang-Wook Nam (CW)

Department of Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.

Giampaolo Niccoli (G)

University of Parma, Parma, Italy.

Masafumi Nakayama (M)

Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan; Toda Central General Hospital, Cardiovascular Center, Toda, Japan.

Nobuhiro Tanaka (N)

Department of Cardiology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Eun-Seok Shin (ES)

Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.

Steven A J Chamuleau (SAJ)

Department of Cardiology, Amsterdam University Medical Center, Academic Medical Center, Amsterdam, the Netherlands; Department of Cardiology, Amsterdam University Medical Center, VU University Medical Center, Amsterdam, the Netherlands.

Niels van Royen (N)

Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.

Paul Knaapen (P)

Department of Cardiology, Amsterdam University Medical Center, VU University Medical Center, Amsterdam, the Netherlands.

Bon Kwon Koo (BK)

Seoul National University Hospital, Department of Internal Medicine, Cardiovascular Center, Seoul, Korea.

Tsunekazu Kakuta (T)

Department of Cardiology, Tsuchiura Kyodo General Hospital, Tsuchiura City, Japan.

Javier Escaned (J)

Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.

Jan J Piek (JJ)

Department of Cardiology, Amsterdam University Medical Center, Academic Medical Center, Amsterdam, the Netherlands.

Tim P van de Hoef (TP)

Department of Cardiology, Amsterdam University Medical Center, Academic Medical Center, Amsterdam, the Netherlands; Department of Cardiology, Amsterdam University Medical Center, VU University Medical Center, Amsterdam, the Netherlands; Department of Cardiology, NoordWest Ziekenhuisgroep, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH